FDA Clears First Blood-Based Biomarker Test for Alzheimer's: What It Means for Patients and Providers Diagnosing Alzheimer’s disease could be as simple as a routine blood draw thanks to the FDA’s recent clearance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio. This innova... Alzheimer's biomarkers diagnostics FDA clearance Fujirebio neurodegenerative diseases plasma test
How Sugars on Cell Surfaces Could Unlock New Paths to Brain Resilience What if a crucial piece in the puzzle of brain aging has been hiding in plain sight, overlooked sugars on the surfaces of our brain cells. While past research zeroed in on proteins and DNA, emerging s... Alzheimer's blood-brain barrier brain aging cell surface sugars cognitive decline drug delivery glycocalyx neurodegeneration
New Genetic Pathways Offer Hope for Alzheimer’s Drug Development Alzheimer’s disease is a condition that affects millions globally and has traditionally been linked to amyloid plaques in the brain. Most drug development efforts have targeted these plaques but real-... Alzheimer's computational biology DNA repair drug discovery genetics neurodegeneration RNA modification
AI Revolutionizes How Scientists Map Protein Locations in Human Cells What if researchers could diagnose diseases or develop breakthrough drugs in a fraction of the time it takes today? Thanks to a cutting-edge artificial intelligence model from MIT, Harvard, and the Br... Alzheimer's artificial intelligence biomedical research cell biology diagnostics drug discovery machine learning protein localization
Shedding New Light on Neural Connections: How LICONN is Democratizing Brain Mapping Imagine unlocking the brain’s secrets with equipment found in a typical biology lab. Recent advances have made this possible by using light microscopy —instead of expensive electron microscopes—to map... Alzheimer's brain mapping connectomics light microscopy machine learning molecular imaging neuroscience synapses tissue expansion